The Phage Therapy Market is witnessing increasing interest as healthcare organizations and biotechnology companies explore innovative approaches for managing bacterial infections. Phage therapy relies on bacteriophages that selectively target bacterial pathogens, making it an attractive research area in the development of alternative antimicrobial solutions.

Antimicrobial resistance is one of the major factors contributing to market interest. The reduced effectiveness of certain conventional antibiotics has encouraged researchers to investigate therapies capable of targeting drug-resistant bacteria. Current market research identifies increasing investments, technological development, and clinical trials as important factors supporting the expansion of phage therapy.

Technological innovation is transforming the industry. Advances in genome sequencing and genetic engineering are enabling researchers to characterize, modify, and develop phages with specific characteristics. Phage cocktails are also being investigated to broaden bacterial coverage and potentially address bacterial resistance.

The market has applications across human healthcare, veterinary medicine, food and beverage, agriculture, and research. In healthcare, research is focused on infections caused by pathogens such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus.

Regional growth is supported by biotechnology investments and increasing research infrastructure. Asia-Pacific is particularly promising because of expanding healthcare capabilities and biotechnology development.

Future opportunities are likely to arise from personalized phage therapies, engineered bacteriophages, combination treatments, improved delivery systems, and collaborations between research organizations and pharmaceutical companies.